ASCO GU 2026 | 翰森制药Risvutatug Rezetecan(B7-H3 ADC)治疗转移性去势抵抗性前列腺癌 (mCRPC)II期临床数据发布

翰森制药
Feb 27

-Risvutatug rezetecan在既往接受新型内分泌药物治疗后进展的转移性去势抵抗性前列腺癌 (mCRPC)患者中展现出抗肿瘤活性,且安全性特征总体可控。2026年2月27日,翰森制药集团有限公司(以下简称“翰森制药”,03692.HK)宣布,其自主研发的 risvutatug rezetecan(HS-20093 / GSK5764227)II期临床研究数据于2026年2月26-28日...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10